ArticleCancer cell2013
The kinase-independent, second life of CDK6 in transcription.
Article in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Identifying therapeutic target genes for stroke through systematic druggable Mendelian randomization analysis.Medicine · 2026Article
- CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.HemaSphere · 2026Article
- Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.Journal of hematology & oncology · 2026Review
- The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer.Nature communications · 2023Article
- How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells.International journal of molecular sciences · 2021Article
- The role of CDK6 in cancer.International journal of cancer · 2020Review
- CDK6 Inhibition: A Novel Approach in AML Management.International journal of molecular sciences · 2020Review
- CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.Frontiers in genetics · 2020Article
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.Expert review of anticancer therapy · 2019Review
- Structural insights into the functional diversity of the CDK-cyclin family.Open biology · 2018Review
- CBX3 promotes colon cancer cell proliferation by CDK6 kinase-independent function during cell cycle.Oncotarget · 2017Article
- BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.Stem cell research & therapy · 2016Article
- Development of a unique epigenetic signature during in vivo Th17 differentiation.Nucleic acids research · 2015Article
- H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.American journal of translational research · 2015Article
- Targeting cell cycle regulators in hematologic malignancies.Frontiers in cell and developmental biology · 2015Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CDK6 is an oncogenic kinase regulating the cell cycle. In this issue of Cancer Cell, Kollmann and colleagues demonstrate that CDK6 performs a kinase-independent transcriptional function in regulating expression of VEGF-A and p16INK4a. These observations link the cell cycle machinery and angiogenesis and reveal the presence of a fail-safe antiproliferative mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.